Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon, Asuragen Ink Deal to Offer microRNA PCR-based Services

NEW YORK (GenomeWeb News) – Exiqon and Asuragen announced today the signing of a service center agreement allowing Asuragen to offer real-time PCR services based on Exiqon's miRcury LNA Universal RT-microRNA PCR products.

Exiqon's technology is used for discovering new biomarkers of diseases and biological processes and combines Universal RT reaction with LNA-enhanced PCR primers. Asuragen Genomic Services Division provides nucleic acid-based services, including biomarker discovery and companion diagnostic development.

Financial and other terms of the deal were not disclosed.

"Exiqon's high-quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners," Carol Berry, SVP and GM of Asuragen Genomic Services Division, said in a statement.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.